Search Results - "Schottstedt, V"

Routine bacterial screening of platelet concentrates by flow cytometry and its impact on product safety and supply by Müller, B., Walther-Wenke, G., Kalus, M., Alt, T., Bux, J., Zeiler, T., Schottstedt, V.

“…Background and Objectives Bacterial contamination represents the major infectious hazard associated with transfusion of platelet concentrates (PCs). As…”
Get full text

P0653 : Performance evaluation of the updated Elecsys Anti-HBs II immunoassay by Mühlbacher, A, Böhm, S, Schottstedt, V, Hirankarn, N, Vandelaer, S.K, Woeste, A

Get full text

Establishment of a proficiency panel for an external quality assessment programme for the detection of bacterial contamination in platelet concentrates using rapid and cultural detection methods by Vollmer, T., Schmidt, M., Hourfar, K., Schottstedt, V., Pichl, L., Gubbe, K., Knabbe, C., Dreier, J.

“…Background Platelet concentrates (PCs) are the main focus regarding the residual risk of transfusion‐transmitted bacterial infections. Rapid screening methods…”
Get full text

Inter-laboratory comparison of different rapid methods for the detection of bacterial contamination in platelet concentrates by Vollmer, T., Hinse, D., Schottstedt, V., Bux, J., Tapernon, K., Sibrowski, W., Knabbe, C., Dreier, J.

“…Background  Bacterial contamination of platelet concentrates still represents a major risk in transfusion medicine, and a variety of screening methods have…”
Get full text

How new is new: the late sampling strategy with rapid bacterial screening of platelet concentrates? by Vollmer, T., Schottstedt, V., Bux, J., Knabbe, C., Dreier, J.

Get full text

Detection of bacterial contamination in platelet concentrates by a sensitive flow cytometric assay (BactiFlow): a multicentre validation study by Vollmer, T., Dreier, J., Schottstedt, V., Bux, J., Tapernon, K., Sibrowski, W., Kleesiek, K., Knabbe, C.

“…Background Bacterial contamination of platelet concentrates (PCs) still represents an ongoing risk. As a result of septic complications, particularly observed…”
Get full text

Serum antibodies to conformational and linear epitopes of myelin oligodendrocyte glycoprotein are not elevated in the preclinical phase of multiple sclerosis by Chan, A., Decard, BF, Franke, C., Grummel, V., Zhou, D., Schottstedt, V., Toyka, KV, Hemmer, B., Gold, R.

“…Background: The proposed predictive value of serum anti-myelin antibodies for the development of multiple sclerosis after a first clinically isolated syndrome…”
Get full text

Sterility screening of platelet concentrates: questioning the optimal test strategy by Dreier, J., Störmer, M., Pichl, L., Schottstedt, V., Grolle, A., Bux, J., Kleesiek, K.

“…Background  Routine bacterial monitoring of apheresis platelet concentrates (APC) and pooled platelet concentrates (PPC) was introduced in two German blood…”
Get full text

Blood donor screening with cobas s 201/cobas TaqScreen MPX under routine conditions at German Red Cross institutes by Schmidt, M., Pichl, L., Jork, C., Hourfar, M. K., Schottstedt, V., Wagner, F. F., Seifried, E., Müller, T. H., Bux, J., Saldanha, J.

“…Background  In 1997 the German Red Cross (GRC) blood donor services introduced mini‐pool nucleic acid testing (NAT) for human immunodeficiency virus (HIV)‐1,…”
Get full text

International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009 by Roth, W. K., Busch, M. P., Schuller, A., Ismay, S., Cheng, A., Seed, C. R., Jungbauer, C., Minsk, P. M., Sondag-Thull, D., Wendel, S., Levi, J. E., Fearon, M., Delage, G., Xie, Y., Jukic′, I., Turek, P., Ullum, H., Tefanova, V., Tilk, M., Reimal, R., Castren, J., Naukkarinen, M., Assal, A., Jork, C., Hourfar, M. K., Michel, P., Offergeld, R., Pichl, L., Schmidt, M., Schottstedt, V., Seifried, E., Wagner, F., Weber-Schehl, M., Politis, C., Lin, C. K., Tsoi, W. C., O'Riordan, J., Gottreich, A., Shinar, E., Yahalom, V., Velati, C., Satake, M., Sanad, N., Sisene, I., Bon, A. H., Koppelmann, M., Flanagan, P., Flesland, O., Brojer, E., Łętowska, M., Nascimento, F., Zhiburt, E., Chua, S. S., Teo, D., Stezinar, S. Levicnik, Vermeulen, M., Reddy, R., Park, Q., Castro, E., Eiras, A., Gonzales Fraile, I., Torres, P., Ekermo, B., Niederhauser, C., Chen, H., Oota, S., Brant, L. J., Eglin, R., Jarvis, L., Mohabir, L., Brodsky, J., Foster, G., Jennings, C., Notari, E., Stramer, S., Kessler, D., Hillyer, C., Kamel, H., Katz, L., Taylor, C., Panzer, S., Reesink, H.W.

Get full text

PCR for HVC, HCV and HIV-1 Experiences and First Results from a Rountine Screening Programme in a Large Blood Transfusion Service by Schottstedt, V., Tuma, W., Bünger, G., Lefèvre, H.

“…We adapted the PCR method to screen up to 3000 blood donations per day for hepatitis B, hepatitis C and HIV-1 virus contamination. Up to 600 aliquots (average…”
Get full text

European multi-centre validation study of NucliSens Extractor in combination with HCV Amplicor 2.0 assay for HCV-NAT screening of plasma pools by Cuypers, H T, van Dijk, R, Viret, J F, Schottstedt, V, Lankinen, M, Da Silva Cardoso, M, Lelie, P N

“…The NucliSens Extractor in combination with the 2.0 version of the Roche Cobas HCV Amplicor test has been validated by five European blood screening…”
Get full text

F08The autoimmune profile of Huntington's disease patients: a pilot study by Goehler, H, Kowald, A, Turewicz, M, Stephan, C, Meyer, HE, Lueking, A, Schottstedt, V, Woitalla, D, Hoffmann, R, Gold, R, Saft, C

“…Huntington's disease (HD) is a progressive neurodegenerative disorder, which is caused by expansion of a polyglutamine tract in the first exon of the…”
Get full text

F08 The autoimmune profile of Huntington's disease patients: a pilot study by Goehler, H, Kowald, A, Turewicz, M, Stephan, C, Meyer, HE, Lueking, A, Schottstedt, V, Woitalla, D, Hoffmann, R, Gold, R, Saft, C

“…Huntington's disease (HD) is a progressive neurodegenerative disorder, which is caused by expansion of a polyglutamine tract in the first exon of the…”
Get full text

Blood donor screening with cobas s 201/cobas TaqScreen MPX under routine conditions at German Red Cross institutes: Multiplex NAT screening in blood donors by Schmidt, M., Pichl, L., Jork, C., Hourfar, M. K., Schottstedt, V., Wagner, F. F., Seifried, E., Müller, T. H., Bux, J., Saldanha, J.

Get full text

Sensitivity of HCV RNA and HIV RNA blood screening assays by Lelie, P. Nico, Van Drimmelen, Harry A.J., Cuypers, H. Theo M., Best, Susan J., Stramer, Susan L., Hyland, Catherine, Allain, Jean-Pierre, Moncharmont, Pierre, Defer, Christine, Nübling, Micha, Glauser, Andreas, Da Silva Cardoso, Marcia, Viret, Jean-François, Lankinen, Mervi H., Grillner, Lena, Wirthmüller, Urs, Coste, Joliette, Schottstedt, Volkmar, Masecar, Barbara, Dax, Elizabeth M.

“…BACKGROUND: The FDA requirement for sensitivity of viral NAT methods used in blood screening is a 95‐percent detection limit of 100 copies per mL, whereas the…”
Get full text

Impact of vCJD on blood supply by Seitz, Rainer, von Auer, Friedger, Blümel, Johannes, Burger, Reinhard, Buschmann, Anne, Dietz, Klaus, Heiden, Margarethe, Hitzler, Walter E., Klamm, Horst, Kreil, Thomas, Kretzschmar, Hans, Nübling, Micha, Offergeld, Ruth, Pauli, Georg, Schottstedt, Volkmar, Volkers, Peter, Zerr, Inga

“…Variant Creutzfeldt–Jakob disease (vCJD) is an at present inevitably lethal neurodegenerative disease which can only be diagnosed definitely post mortem. The…”
Get full text

PCR for HBV, HCV and HIV-1 experiences and first results from a routine screening programme in a large blood transfusion service by Schottstedt, V, Tuma, W, Bünger, G, Lefèvre, H

“…We adapted the PCR method to screen up to 3000 blood donations per day for hepatitis B, hepatitis C and HIV-1 virus contamination. Up to 600 aliquots (average…”
Get full text

European Multi-Centre Validation Study of NucliSens Extractor in Combination with HCV Amplicor 2·0 Assay for HCV-NAT Screening of Plasma Pools by Cuypers, H.T.M., van Dijk, R., Viret, J-F., Schottstedt, V., Lankinen, M., Da Silva Cardoso, M., Lelie, P.N.

“…The NucliSens Extractor in combination with the 2·0 version of the Roche Cobas HCV Amplicor test has been validated by five European blood screening…”
Get full text

Routine PCR screening for HBV, HCV and HIV-I genome in a large blood donation services--experiences and initial results by Schottstedt, V, Tuma, W, Bünger, G, Lakenberg, P

“…We adapted the PCR method to screen up to 3,000 blood donations per day for HBV, HCV, and HIV-1 contamination. Concerning logistics: The first step is the…”
Get more information